pemirolast has been researched along with paclitaxel in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goromaru, T; Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Sendo, T; Takasaki, S | 1 |
| Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Saito, M; Sendo, T; Uchida, M; Yahata, H | 1 |
| Egashira, N; Kawashiri, T; Oishi, R; Yano, T | 1 |
1 trial(s) available for pemirolast and paclitaxel
| Article | Year |
|---|---|
Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Ovarian Neoplasms; Paclitaxel; Placebos; Pyridines; Pyrimidinones | 2006 |
2 other study(ies) available for pemirolast and paclitaxel
| Article | Year |
|---|---|
Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Dose-Response Relationship, Drug; Drug Hypersensitivity; Male; Neurokinin A; Neuropeptides; Paclitaxel; Pyridines; Pyrimidinones; Rats; Rats, Sprague-Dawley; Substance P | 2004 |
[Substance P in antitumor drug-induced adverse reactions].
Topics: Animals; Antineoplastic Agents; Carboplatin; Histamine Antagonists; Humans; Nausea; Neuropeptides; Paclitaxel; Pyridines; Pyrimidinones; Substance P; Vomiting | 2013 |